Clinical Trial Update: To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing palbociclib alone versus in combination with endocrine therapy for reversing endocrine resistance in breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Palbociclib (palbociclib)

Snippet

Sponsor: Fondazione Sandro Pitigliani | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED